Abstract
Intraneuronal amyloid-β (iAβ) accumulation has been demonstrated in Alzheimer disease (AD). Although extracellular amyloid plaques composed primarily of aggregated amyloid-β are one of the main pathological features of AD, functional characterization of iAβ is still lacking. In this study, we identified the normal distribution of iAβ through an analysis of hippocampal sections from a series of over 90 subjects with diverse antemortem clinical findings. In addition to AD cases, iAβ in pyramidal neurons was readily and reproducibly demonstrated in the majority of control cases. Similar findings for controls were made across all ages, spanning from infants to the elderly. There was no correlation of iAβ between gender, postmortem interval, or age. While the possible pathophysiological significance of iAβ accumulation in AD remains to be elucidated, careful examination of iAβ found in the normal brain may be informative for determining the biological role of iAβ and how this function changes during disease. Current findings support a physiological role for iAβ in neuronal function over the entire lifespan.
Keywords: Aging, Alzheimer disease, amyloid-β, amyloid-β protein precursor, immunohistochemistry, neuropathology.
Current Alzheimer Research
Title:Accumulation of Intraneuronal Amyloid-β is Common in Normal Brain
Volume: 11 Issue: 4
Author(s): Jeffrey A. Blair, Sandra L. Siedlak, Julie A. Wolfram, Akihiko Nunomura, Rudy J. Castellani, Sergio T. Ferreira, William L. Klein, Yang Wang, Gemma Casadesus, Mark A. Smith, George Perry, Xiongwei Zhu and Hyoung-gon Lee
Affiliation:
Keywords: Aging, Alzheimer disease, amyloid-β, amyloid-β protein precursor, immunohistochemistry, neuropathology.
Abstract: Intraneuronal amyloid-β (iAβ) accumulation has been demonstrated in Alzheimer disease (AD). Although extracellular amyloid plaques composed primarily of aggregated amyloid-β are one of the main pathological features of AD, functional characterization of iAβ is still lacking. In this study, we identified the normal distribution of iAβ through an analysis of hippocampal sections from a series of over 90 subjects with diverse antemortem clinical findings. In addition to AD cases, iAβ in pyramidal neurons was readily and reproducibly demonstrated in the majority of control cases. Similar findings for controls were made across all ages, spanning from infants to the elderly. There was no correlation of iAβ between gender, postmortem interval, or age. While the possible pathophysiological significance of iAβ accumulation in AD remains to be elucidated, careful examination of iAβ found in the normal brain may be informative for determining the biological role of iAβ and how this function changes during disease. Current findings support a physiological role for iAβ in neuronal function over the entire lifespan.
Export Options
About this article
Cite this article as:
Blair A. Jeffrey, Siedlak L. Sandra, Wolfram A. Julie, Nunomura Akihiko, Castellani J. Rudy, Ferreira T. Sergio, Klein L. William, Wang Yang, Casadesus Gemma, Smith A. Mark, Perry George, Zhu Xiongwei and Lee Hyoung-gon, Accumulation of Intraneuronal Amyloid-β is Common in Normal Brain, Current Alzheimer Research 2014; 11 (4) . https://dx.doi.org/10.2174/1567205011666140302200902
DOI https://dx.doi.org/10.2174/1567205011666140302200902 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pesticides-induced Cardiovascular Dysfunctions: Prevalence and Associated Mechanisms
Current Hypertension Reviews Stem Cell Therapy for the Treatment of Myocardial Infarction
Current Pharmaceutical Design Propranolol Safety Profile in Children
Current Drug Safety Chemokines in Cardiovascular Remodeling: Clinical and Therapeutic Implications
Current Molecular Medicine Fatty Liver and Ischemia/Reperfusion: Are there Drugs Able to Mitigate Injury?
Current Medicinal Chemistry L-Carnitine - Metabolic Functions and Meaning in Humans Life
Current Drug Metabolism Targeting Na/K-ATPase Signaling: A New Approach to Control Oxidative Stress
Current Pharmaceutical Design Genomic and Non-genomic Effects of Aldosterone
Current Signal Transduction Therapy Forensic Toxicology and Pharmacogenomics: Hype or Hope For Higher Standards in Forensic Medicine?
Current Pharmacogenomics and Personalized Medicine Positron Emitting Tracers in Pre-Clinical Drug Development
Current Radiopharmaceuticals Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Human Tissue Kallikrein: A New Bullet for the Treatment of Ischemia
Current Pharmaceutical Design Myocardial Infarction in Systemic Lupus Erythematosus – the Sex-Specific Risk Profile
Current Pharmaceutical Design Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Cardiolipin Metabolism and the Role it Plays in Heart Failure and Mitochondrial Supercomplex Formation
Cardiovascular & Hematological Disorders-Drug Targets Editorial from Guest Editor [Hot topic: Novel Inflammatory Biomarkers in Diseases (Guest Editor: Yu Chen)]
Inflammation & Allergy - Drug Targets (Discontinued) New Insights into the Role of FGF-23 and Klotho in Cardiovascular Disease in Chronic Kidney Disease Patients
Current Vascular Pharmacology Relationship of High-Sensitivity C-Reactive Protein Concentrations and Systolic Heart Failure
Current Vascular Pharmacology Acute Cardioembolic Cerebral Infarction: Answers to Clinical Questions
Current Cardiology Reviews Big Data and Genome Editing Technology: A New Paradigm of Cardiovascular Genomics
Current Cardiology Reviews